AstraZeneca PLC (AZN)
| Market Cap | 212.62B |
| Revenue (ttm) | 45.81B |
| Net Income (ttm) | 5.96B |
| Shares Out | 3.10B |
| EPS (ttm) | 1.91 |
| PE Ratio | 35.79 |
| Forward PE | 16.31 |
| Dividend | $1.45 (2.11%) |
| Ex-Dividend Date | Feb 22, 2024 |
| Volume | 3,247,419 |
| Open | 68.14 |
| Previous Close | 68.36 |
| Day's Range | 68.13 - 68.71 |
| 52-Week Range | 60.47 - 76.56 |
| Beta | 0.19 |
| Analysts | Buy |
| Price Target | 81.67 (+19.08%) |
| Earnings Date | Apr 25, 2024 |
About AZN
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus... [Read more]
Financial Performance
In 2023, AstraZeneca's revenue was $45.81 billion, an increase of 3.29% compared to the previous year's $44.35 billion. Earnings were $5.96 billion, an increase of 81.11%.
Financial StatementsAnalyst Forecast
According to 6 analysts, the average rating for AZN stock is "Buy." The 12-month stock price forecast is $81.67, which is an increase of 19.08% from the latest price.
News
Big pharma is looking to fatten profits with buyouts of weight-loss drug companies. Here are 4 candidates.
A couple of big-picture trends in biotech could add up to a nice investment opportunity. First, corporate buyouts are back in style.
Asher Bio Closes $55 Million Series C Financing to Advance Lead Program into Phase 1b Clinical Trials
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Asher Biotherapeutics, a biotechnology company developing precisely-targeted immunotherapies for cancer, autoimmune, and infectious diseases, today announ...
IMFINZI® (durvalumab) plus chemotherapy doubled overall survival rate at three years for patients with advanced biliary tract cancer in TOPAZ-1 Phase III trial
WILMINGTON, Del.--(BUSINESS WIRE)--Updated exploratory results from the TOPAZ-1 Phase III trial showed AstraZeneca's IMFINZI® (durvalumab) in combination with standard-of-care chemotherapy demonstrate...
No Evidence Linking Ozempic And Suicidal Thoughts, EU Says
There is no evidence linking diabetes and weight loss drugs like Ozempic and Wegovy to an increase in suicidal thoughts, the European Union's drug regulator said Friday, the latest findings casting do...
FASENRA approved for treatment of children aged 6 to 11 with severe asthma
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca's FASENRA® (benralizumab) is now approved by the US Food and Drug Administration (FDA) for add-on maintenance treatment for patients with severe asthma a...
AstraZeneca unveils dividend hike ahead of CEO pay vote at AGM
AstraZeneca said on Thursday it intends to increase annual dividend for 2024 by 7% to $3.10 per share, betting on strong performance and cash generation on the back of its blockbuster drugs and severa...
Eli Lilly's and AstraZeneca's Former Head of Research Dr. Jan Lundberg Invests in AlzeCure and is Proposed for Election to its Board
STOCKHOLM, SWEDEN / ACCESSWIRE / April 10, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB ("AlzeCure" or "the Company"), a pharmaceutical company that develops candidate drugs for CNS...
ENHERTU® Approved in the U.S. as First Tumor Agnostic HER2 Directed Therapy for Previously Treated Patients with Metastatic HER2 Positive Solid Tumors
TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--ENHERTU® Approved in the U.S. as First Tumor Agnostic HER2 Directed Therapy for Previously Treated Patients with Metastatic HER2+ Solid Tumors.
ENHERTU® (fam-trastuzumab deruxtecan-nxki) approved in the US as first tumor-agnostic HER2-directed therapy for previously treated patients with metastatic HER2-positive solid tumors
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca and Daiichi Sankyo's ENHERTU® (fam-trastuzumab deruxtecan-nxki) has been approved in the US for the treatment of adult patients with unresectable or meta...
US FDA approves Daiichi, AstraZeneca drug for treatment of solid tumors
The U.S. Food and Drug Administration on Friday gave accelerated approval for the expanded use of Daiichi Sankyo and AstraZeneca's drug to treat patients with a type of solid tumor.
AstraZeneca's Imfinzi shows promise in treating aggressive lung cancer
Drugmaker AstraZeneca said on Friday its blockbuster cancer drug Imfinzi showed "significant and clinically meaningful" improvement in the primary goals of a late-stage trial designed for an aggressiv...
Healthy Returns: Weight loss, diabetes drug ad spending tops $1 billion
Drugmakers spent big on ads for weight loss and diabetes drugs such as Wegovy and Ozempic. Meanwhile, the FDA approved the first AI diagnostic tool for sepsis.
Datopotamab deruxtecan Biologics License Application accepted in the US for patients with previously treated metastatic HR-positive, HER2-negative breast cancer
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca and Daiichi Sankyo's Biologics License Application (BLA) for datopotamab deruxtecan (Dato-DXd) has been accepted in the US for the treatment of adult pat...
Datopotamab Deruxtecan Biologics License Application Accepted in the U.S. for Patients with Previously Treated Metastatic HR Positive, HER2 Negative Breast Cancer
TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--Daiichi Sankyo (TSE: 4568) and AstraZeneca's (LSE/STO/Nasdaq: AZN) Biologics License Application (BLA) for datopotamab deruxtecan (Dato-DXd) has been acce...
VOYDEYA™ approved in the US as add-on therapy to ravulizumab or eculizumab for treatment of extravascular hemolysis in adults with the rare disease PNH
WILMINGTON, Del.--(BUSINESS WIRE)--VOYDEYA™ (danicopan) has been approved in the US as add-on therapy to ravulizumab or eculizumab for the treatment of extravascular hemolysis (EVH) in adults with par...
AstraZeneca CEO Soriot on Pharmaceuticals in China
AstraZeneca CEO Pascal Soriot discusses the drugmaker's business strategy in China, the US “BIOSECURE Act,” and future deals and partnerships in China. He speaks with Stephen Engle on the sidelines of...
AstraZeneca: Fusion acquisition will be a cost effective-investment that can improve cancer outcomes
Dr. Susan Galbraith, executive vice-president of oncology and R&D at AstraZeneca, discusses the healthcare giant's $2.4bn acquisition of Fusion Pharmaceuticals.
AstraZeneca to acquire Fusion to accelerate the development of next-generation radioconjugates to treat cancer
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca has entered into a definitive agreement to acquire Fusion Pharmaceuticals Inc., a clinical-stage biopharmaceutical company developing next-generation rad...
AstraZeneca to buy Fusion Pharmaceuticals for up to $2.4 billion
AstraZeneca is buying Fusion Pharmaceuticals for $2.4 billion as the London-listed group looks to build its presence in cutting-edge cancer treatments.
AstraZeneca to buy Fusion Pharma for $2 billion in cash
AstraZeneca said on Tuesday it will buy clinical-stage biopharmaceutical company Fusion Pharmaceuticals Inc for about $2 billion in cash to boost its oncology portfolio.
AstraZeneca to cap US out-of-pocket costs for inhalers to $35
AstraZeneca said on Monday it would cap out-of-pocket costs for its inhaled respiratory products for chronic lung disease and asthma to $35 per month, starting June, in the United States.
AstraZeneca caps patient out-of-pocket costs at $35 per month for its US inhaled respiratory portfolio
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca announced it will expand the savings programs for its entire US inhaled respiratory portfolio, helping eligible patients pay no more than $35 per month f...
AstraZeneca To Buy Amolyt Pharma for $1.05B To Expand Rare Disease Pipeline
AstraZeneca PLC (AZN) plans to acquire biotech firm Amolyt Pharma for $1.05 billion in cash, the drugmaker said Thursday, boosting its pipeline of drugs to treat rare diseases.
Sofinnova Partners Portfolio Company Amolyt Pharma to be Acquired by AstraZeneca
PARIS--(BUSINESS WIRE)-- #VC--Sofinnova Partners announced that its portfolio company, Amolyt Pharma, has entered into a definitive agreement with AstraZeneca for its acquisition.